Clinical Cancer Research, Vol 3, Issue 6 881-890, Copyright © 1997 by American Association for Cancer Research

ARTICLES

In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin

B Waurzyniak, EA Schneider, N Tumer, Y Yanishevski, R Gunther, LM Chelstrom, H Wendorf, DE Myers, JD Irvin, Y Messinger, O Ek, T Zeren, MC Langlie, WE Evans and FM Uckun
Hughes Institute, St. Paul, Minnesota 55113, USA.

We evaluated the TXU (anti-CD7)-pokeweed antiviral protein (PAP) immunotoxin in both murine and nonhuman primate models. TXU-PAP caused dose-limiting cardiac toxicity in BALB/c mice. In a SCID mouse model of invariably fatal human T-lineage acute lymphoblastic leukemia (ALL), TXU-PAP therapy resulted in a marked improvement of leukemia-free survival without any side effects. Whereas 100% of control mice treated with PBS, unconjugated TXU antibody, or B43-PAP (an immunotoxin that does not react with T-lineage ALL cells) died of disseminated human leukemia within 80 days (median survival, 37 days), 80 +/- 13% of SCID mice treated with 15 microgram of TXU-PAP (median survival, >120 days) and 100% of mice treated with 30 microgram of TXU-PAP (median survival, > 120 days) remained alive and free of leukemia for >120 days. In cynomolgus monkeys, TXU-PAP showed favorable pharmacokinetics with an elimination half-life of 8.1-8.7 h. The monkeys treated with TXU-PAP at dose levels of 0.05 mg/kg/day x 5 days and 0.10 mg/kg/day x 5 days tolerated the therapy very well, without any significant clinical compromise or side effects, and at necropsy, no gross or microscopic lesions were found. This study provides a basis for further evaluation of TXU-PAP as an investigational biotherapeutic agent in the treatment of T-lineage ALL.

This article has been cited by other articles:

				E. Bremer, B. t. Cate, D. F. Samplonius, L. F. M. H. de Leij, and W. Helfrich CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia Blood, April 1, 2006; 107(7): 2863 - 2870. [Abstract] [Full Text] [PDF]

				E. Bremer, D. F. Samplonius, M. Peipp, L. van Genne, B.-J. Kroesen, G. H. Fey, M. Gramatzki, L. F.M.H. de Leij, and W. Helfrich Target Cell-Restricted Apoptosis Induction of Acute Leukemic T Cells by a Recombinant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Fusion Protein with Specificity for Human CD7 Cancer Res., April 15, 2005; 65(8): 3380 - 3388. [Abstract] [Full Text] [PDF]

				K. A. Hudak, B. A. Parikh, R. Di, M. Baricevic, M. Santana, M. Seskar, and N. E. Tumer Generation of pokeweed antiviral protein mutations in Saccharomyces cerevisiae: evidence that ribosome depurination is not sufficient for cytotoxicity Nucleic Acids Res., August 10, 2004; 32(14): 4244 - 4256. [Abstract] [Full Text] [PDF]

				P. J. Houghton, P. C. Adamson, S. Blaney, H. A. Fine, R. Gorlick, M. Haber, L. Helman, S. Hirschfeld, M. G. Hollingshead, M. A. Israel, et al. Testing of New Agents in Childhood Cancer Preclinical Models: Meeting Summary Clin. Cancer Res., December 1, 2002; 8(12): 3646 - 3657. [Abstract] [Full Text] [PDF]

				B. A. Parikh, C. Coetzer, and N. E. Tumer Pokeweed Antiviral Protein Regulates the Stability of Its Own mRNA by a Mechanism That Requires Depurination but Can Be Separated from Depurination of the alpha -Sarcin/Ricin Loop of rRNA J. Biol. Chem., October 25, 2002; 277(44): 41428 - 41437. [Abstract] [Full Text] [PDF]

				M. Peipp, H. Kupers, D. Saul, B. Schlierf, J. Greil, S. J. Zunino, M. Gramatzki, and G. H. Fey A Recombinant CD7-specific Single-Chain Immunotoxin Is a Potent Inducer of Apoptosis in Acute Leukemic T Cells Cancer Res., May 1, 2002; 62(10): 2848 - 2855. [Abstract] [Full Text] [PDF]

				R. K. Narla, C.-L. Chen, Y. Dong, and F. M. Uckun In Vivo Antitumor Activity of Bis(4,7-dimethyl-1,10-phenanthroline) Sulfatooxovanadium(IV) {METVAN [VO(SO4)(Me2-Phen)2]} Clin. Cancer Res., July 1, 2001; 7(7): 2124 - 2133. [Abstract] [Full Text] [PDF]

				R. K. Narla, Y. Dong, D. Klis, and F. M. Uckun Bis(4,7-dimethyl-1,10-phenanthroline) Sulfatooxovanadium(IV) as a Novel Antileukemic Agent with Matrix Metalloproteinase Inhibitory Activity Clin. Cancer Res., April 1, 2001; 7(4): 1094 - 1101. [Abstract] [Full Text]

				R. K. Narla, Y. Dong, O. J. D’Cruz, C. Navara, and F. M. Uckun Bis(4,7-dimethyl-1,10-phenanthroline) Sulfatooxovanadium(IV) as a Novel Apoptosis-inducing Anticancer Agent Clin. Cancer Res., April 1, 2000; 6(4): 1546 - 1556. [Abstract] [Full Text]

				A. E. Frankel, R. J. Kreitman, and E. A. Sausville Targeted Toxins Clin. Cancer Res., February 1, 2000; 6(2): 326 - 334. [Abstract] [Full Text]

				F. M. Uckun, K. Bellomy, K. O'Neill, Y. Messinger, T. Johnson, and C.-L. Chen Toxicity, Biological Activity, and Pharmacokinetics of TXU (Anti-CD7)-Pokeweed Antiviral Protein in Chimpanzees and Adult Patients Infected with Human Immunodeficiency Virus J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1301 - 1307. [Abstract] [Full Text]

				F. M. Uckun, L. M. Chelstrom, L. Tuel-Ahlgren, I. Dibirdik, J. D. Irvin, M.-C. Langlie, and D. E. Myers TXU (Anti-CD7)-Pokeweed Antiviral Protein as a Potent Inhibitor of Human Immunodeficiency Virus Antimicrob. Agents Chemother., February 1, 1998; 42(2): 383 - 388. [Abstract] [Full Text]

				F. M. Uckun, M. G. Sensel, L. Sun, P. G. Steinherz, M. E. Trigg, N. A. Heerema, H. N. Sather, G. H. Reaman, and P. S. Gaynon Biology and Treatment of Childhood T-Lineage Acute Lymphoblastic Leukemia Blood, February 1, 1998; 91(3): 735 - 746. [Full Text] [PDF]